West Pharmaceutical
757 hedge funds and large institutions have $25.8B invested in West Pharmaceutical in 2023 Q3 according to their latest regulatory filings, with 83 funds opening new positions, 244 increasing their positions, 303 reducing their positions, and 51 closing their positions.
63% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 51
22% more call options, than puts
Call options by funds: $89.2M | Put options by funds: $72.9M
3% more funds holding
Funds holding: 734 → 757 (+23)
0.83% more ownership
Funds ownership: 91.76% → 92.59% (+0.83%)
1% less capital invested
Capital invested by funds: $26B → $25.8B (-$210M)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
19% less repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 303
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$224M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$222M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$193M |
| 4 |
GCM
Gladstone Capital Management
London,
United Kingdom
|
+$86M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$80.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$128M |
| 2 |
Millennium Management
New York
|
-$100M |
| 3 |
Man Group
London,
United Kingdom
|
-$97.2M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$92.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$80M |
WST Hedge Fund Activity: Q3 2023 in Review
757 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2023, worth a combined $25.8B — down 0.81% from $26B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new WST positions and 51 closed out — a net gain of 32 holders — while 244 added to existing stakes and 303 trimmed.
The largest buyer was Artisan Partners, adding an estimated $224M. The largest seller was T. Rowe Price Associates, cutting an estimated $128M.
- 757 institutional investors held West Pharmaceutical (WST) as of Q3 2023, up from 734 in Q2 2023.
- Funds reported $25.8B of West Pharmaceutical stock for Q3 2023, down 0.81% quarter-over-quarter.
- 83 funds opened new West Pharmaceutical positions in Q3 2023 and 51 closed out, a net change of +32 holders.
- The largest West Pharmaceutical buyer in Q3 2023 was Artisan Partners, an estimated $224M added.
- The largest West Pharmaceutical seller in Q3 2023 was T. Rowe Price Associates, an estimated $128M sold.
Based on aggregated 13F filings for Q3 2023.